An overview of triple negative breast cancer for surgical oncologists

Area of Science:

• Oncology
• Genetics
• Medical Research

Background:

• Triple negative breast cancer (TNBC) is defined by the absence of estrogen receptor (ER), progesterone receptor (PR), and HER2 expression.
• TNBC accounts for a significant proportion of breast cancer cases and is associated with poorer prognoses compared to other subtypes.
• Understanding TNBC's unique characteristics is crucial for developing targeted therapies.

Purpose of the Study:

• To provide surgical oncologists with a comprehensive overview of recent advancements in TNBC diagnosis and management.
• To discuss the various subtypes of TNBC and their association with the BRCA1 gene.
• To explore emerging therapeutic strategies aimed at improving outcomes for TNBC patients.

Main Methods:

• Literature review of recent studies and clinical trials on TNBC.
• Analysis of diagnostic criteria and current management guidelines for TNBC.
• Synthesis of information on surgical, radiation, and medical oncology treatment approaches.

Main Results:

• TNBC exhibits diverse subtypes, some linked to BRCA1 mutations, influencing treatment response.
• Recent advances include targeted therapies and immunotherapies showing promise in clinical trials.
• Multidisciplinary approaches integrating surgery, radiation, and medical oncology are essential for optimal care.

Conclusions:

• Continued research into TNBC subtypes and genetic associations is vital.
• Novel therapeutic strategies are transforming TNBC management, offering new hope for patients.
• Early and accurate diagnosis coupled with personalized treatment plans can significantly enhance survival rates and quality of life for TNBC patients.